<?xml version='1.0' encoding='utf-8'?>
<document id="18384443"><sentence text="Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia."><entity charOffset="11-19" id="DDI-PubMed.18384443.s1.e0" text="imatinib" /><entity charOffset="56-66" id="DDI-PubMed.18384443.s1.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.18384443.s1.e0" e2="DDI-PubMed.18384443.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s1.e0" e2="DDI-PubMed.18384443.s1.e1" /></sentence><sentence text="Imatinib, a tyrosine kinase inhibitor, exhibits a competitive inhibition on the CYP450 2D6 isozyme with a K(i) value of 7"><entity charOffset="0-8" id="DDI-PubMed.18384443.s2.e0" text="Imatinib" /><entity charOffset="12-20" id="DDI-PubMed.18384443.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.18384443.s2.e0" e2="DDI-PubMed.18384443.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s2.e0" e2="DDI-PubMed.18384443.s2.e1" /></sentence><sentence text="5 microm" /><sentence text=" However, the clinical significance of the inhibition and its relevance to 2D6 polymorphisms have not been evaluated" /><sentence text=" The pharmacokinetics of imatinib have been well studied in Caucasians, but not in a Chinese population"><entity charOffset="25-33" id="DDI-PubMed.18384443.s5.e0" text="imatinib" /></sentence><sentence text=" Metoprolol, a CYP2D6 substrate, has different clearances among patients with different CYP2D6 genotypes"><entity charOffset="1-11" id="DDI-PubMed.18384443.s6.e0" text="Metoprolol" /></sentence><sentence text=" It is often used as a CYP2D6 probe substrate for clinical drug-drug interaction studies" /><sentence text="" /><sentence text="Co-administration of imatinib at 400 mg twice daily increased the plasma AUC of metoprolol by approximately 23% in 20 Chinese patients with chronic myeloid leukaemia (CML), about 17% increase in CYP2D6 intermediate metabolizers (IMs) (n = 6), 24% in extensive metabolizers (EMs) (n = 13), and 28% for the subject with unknown 2D6 status (n = 1) suggesting that imatinib has a weak to moderate inhibition on CYP2D6 in vivo"><entity charOffset="21-29" id="DDI-PubMed.18384443.s9.e0" text="imatinib" /><entity charOffset="80-90" id="DDI-PubMed.18384443.s9.e1" text="metoprolol" /><entity charOffset="361-369" id="DDI-PubMed.18384443.s9.e2" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.18384443.s9.e0" e2="DDI-PubMed.18384443.s9.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s9.e0" e2="DDI-PubMed.18384443.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18384443.s9.e0" e2="DDI-PubMed.18384443.s9.e2" /><pair ddi="false" e1="DDI-PubMed.18384443.s9.e1" e2="DDI-PubMed.18384443.s9.e1" /><pair ddi="false" e1="DDI-PubMed.18384443.s9.e1" e2="DDI-PubMed.18384443.s9.e2" /></sentence><sentence text=" * The clearance of imatinib in Chinese patients with CML showed no difference between CYP2D6 IMs and EMs, and no major difference from Caucasian patients with CML based on data reported in the literature"><entity charOffset="20-28" id="DDI-PubMed.18384443.s10.e0" text="imatinib" /></sentence><sentence text=" AIMS To investigate the effect of imatinib on the pharmacokinetics of a CYP2D6 substrate, metoprolol, in patients with chronic myeloid leukaemia (CML)"><entity charOffset="35-43" id="DDI-PubMed.18384443.s11.e0" text="imatinib" /><entity charOffset="91-101" id="DDI-PubMed.18384443.s11.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.18384443.s11.e0" e2="DDI-PubMed.18384443.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s11.e0" e2="DDI-PubMed.18384443.s11.e1" /></sentence><sentence text=" The pharmacokinetics of imatinib were also studied in these patients"><entity charOffset="25-33" id="DDI-PubMed.18384443.s12.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="Patients (n = 20) received a single oral dose of metoprolol 100 mg on day 1 after an overnight fast"><entity charOffset="49-59" id="DDI-PubMed.18384443.s14.e0" text="metoprolol" /></sentence><sentence text=" On days 2-10, imatinib 400 mg was administered twice daily" /><sentence text=" On day 8, another 100 mg dose of metoprolol was administered 1 h after the morning dose of imatinib 400 mg"><entity charOffset="34-44" id="DDI-PubMed.18384443.s16.e0" text="metoprolol" /><entity charOffset="92-100" id="DDI-PubMed.18384443.s16.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.18384443.s16.e0" e2="DDI-PubMed.18384443.s16.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s16.e0" e2="DDI-PubMed.18384443.s16.e1" /></sentence><sentence text=" Blood samples for metoprolol and alpha-hydroxymetoprolol measurement were taken on study days 1 and 8, and on day 8 for imatinib"><entity charOffset="19-29" id="DDI-PubMed.18384443.s17.e0" text="metoprolol" /><entity charOffset="34-57" id="DDI-PubMed.18384443.s17.e1" text="alpha-hydroxymetoprolol" /><entity charOffset="121-129" id="DDI-PubMed.18384443.s17.e2" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.18384443.s17.e0" e2="DDI-PubMed.18384443.s17.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s17.e0" e2="DDI-PubMed.18384443.s17.e1" /><pair ddi="false" e1="DDI-PubMed.18384443.s17.e0" e2="DDI-PubMed.18384443.s17.e2" /><pair ddi="false" e1="DDI-PubMed.18384443.s17.e1" e2="DDI-PubMed.18384443.s17.e1" /><pair ddi="false" e1="DDI-PubMed.18384443.s17.e1" e2="DDI-PubMed.18384443.s17.e2" /></sentence><sentence text="" /><sentence text="Of the 20 patients enrolled, six patients (30%) were CYP2D6 intermediate metabolizers (IMs), 13 (65%) extensive metabolizers (EMs), and the CYP2D6 status in one patient was unknown" /><sentence text=" In the presence of 400 mg twice daily imatinib, the mean metoprolol AUC was increased by 17% in IMs (from 1190 to 1390 ng ml(-1) h), and 24% in EMs (from 660 to 818 ng ml(-1) h)"><entity charOffset="39-47" id="DDI-PubMed.18384443.s20.e0" text="imatinib" /><entity charOffset="58-68" id="DDI-PubMed.18384443.s20.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.18384443.s20.e0" e2="DDI-PubMed.18384443.s20.e0" /><pair ddi="false" e1="DDI-PubMed.18384443.s20.e0" e2="DDI-PubMed.18384443.s20.e1" /></sentence><sentence text=" Patients classified as CYP2D6 IMs had an approximately 1" /><sentence text="8-fold higher plasma metoprolol exposure than those classified as EMs"><entity charOffset="21-31" id="DDI-PubMed.18384443.s22.e0" text="metoprolol" /></sentence><sentence text=" The oral clearance of imatinib was 11"><entity charOffset="23-31" id="DDI-PubMed.18384443.s23.e0" text="imatinib" /></sentence><sentence text="0 +/- 2" /><sentence text="0 l h(-1) and 11" /><sentence text="8 +/- 4" /><sentence text="1 l h(-1) for CYP2D6 IMs and EMs, respectively" /><sentence text="" /><sentence text="Co-administration of a high dose of imatinib resulted in a small or moderate increase in metoprolol plasma exposure in all patients regardless of CYP2D6 status"><entity charOffset="36-44" id="DDI-PubMed.18384443.s29.e0" text="imatinib" /></sentence><sentence text=" The clearance of imatinib showed no difference between CYP2D6 IMs and EMs"><entity charOffset="18-26" id="DDI-PubMed.18384443.s30.e0" text="imatinib" /></sentence><sentence text="" /></document>